Trial · NCT03948178
Results by group55
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 55
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adverse Events Recording | Levosimendan | 161 | Participants | ||
| Pulse/Heart Rate Assessment | Levosimendan | Change in pulse rate at week 2 | 7.0 | Standard Deviation 8.8 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in pulse rate at 4 weeks | 10.0 | Standard Deviation 10.4 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in pulse rate at week 6 | 8.5 | Standard Deviation 12.0 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | chnage in pulse rate at Month 3 | 10.4 | Standard Deviation 10.6 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in pulse rate at month 6 | 12.8 | Standard Deviation 10.6 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in pulse rate at end-of-study | 3.5 | Standard Deviation 12.6 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in Heart rate at week 2 | 9.1 | Standard Deviation 10.1 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in Heart rate at week 4 | 12.8 | Standard Deviation 9.4 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in heart rate at Month 3 | 12.6 | Standard Deviation 9.3 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in heart rate at month 6 | 15.0 | Standard Deviation 9.9 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Change in heart rate at end-of-study | 5.3 | Standard Deviation 10.9 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Baseline supine pulse rate | 75.8 | Standard Deviation 12.5 | beats per minute (bpm) |
| Pulse/Heart Rate Assessment | Levosimendan | Baseline supine heart rate | 73.5 | Standard Deviation 12.0 | beats per minute (bpm) |
| 12-lead Electrocardiogram Assessments | Levosimendan | Baseline abnormal ECG | 69 | Participants | |
| 12-lead Electrocardiogram Assessments | Levosimendan | Week 2 abnormal ECG | 56 | Participants | |
| 12-lead Electrocardiogram Assessments | Levosimendan | Week 4 abnormal ECG | 43 | Participants | |
| 12-lead Electrocardiogram Assessments | Levosimendan | Month 3 abnormal ECG | 27 | Participants | |
| 12-lead Electrocardiogram Assessments | Levosimendan | Month 6 abnormal ECG | 11 | Participants | |
| 12-lead Electrocardiogram Assessments | Levosimendan | End-of study abnormal ECG | 36 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03948178/results